Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Nov 24, 2023; 14(11): 445-458
Published online Nov 24, 2023. doi: 10.5306/wjco.v14.i11.445
Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis
Yu-Rui Chen, Zu-Xin Xu, Li-Xin Jiang, Zhi-Wei Dong, Peng-Fei Yu, Zhi Zhang, Guo-Li Gu
Yu-Rui Chen, Li-Xin Jiang, Department of General Surgery, Air Force Clinical College, China Medical University, Beijing 100142, China
Zu-Xin Xu, Guo-Li Gu, Department of General Surgery, Fifth Clinical College (Air Force Clinical College) of Anhui Medical University, Beijing 100142, China
Zhi-Wei Dong, Peng-Fei Yu, Zhi Zhang, Guo-Li Gu, Department of General Surgery, Air Force Medical Center, Air Force Clinical College of China Medical University, Beijing 100142, China
Co-first authors: Yu-Rui Chen and Zu-Xin Xu.
Author contributions: Chen YR and Xu ZX contributed equally to this study, and share joint first authorship; Gu GL designed the research; Chen YR and Xu ZX conceived the study, developed the methodology, collected data, analyzed and interpreted data, and wrote the manuscript; Jiang LX, Zhang Z, Yu PF and Dong ZW collected and analyzed the clinical data; Gu GL and Dong ZW provided the material support, and revised the manuscript. All authors reviewed the results and approved the final version of the manuscript.
Supported by Outstanding Young Talents Program of Air Force Medical Center, PLA, No. 22BJQN004; Clinical Program of Air Force Medical University, No. Xiaoke2022-07.
Institutional review board statement: The study was approved by the ethics committee of the Air Force Medical Center, Chinese People's Liberation Army (Beijing, China).
Informed consent statement: Consent was obtained from patients or their relatives for publication of this report.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author kzggl@163.com.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guo-Li Gu, Doctor, MD, Chief Doctor, Department of General Surgery, Air Force Medical Center, Air Force Clinical College of China Medical University, No. 30 Fucheng Road, Haidian District, Beijing 100142, China. kzggl@163.com
Received: September 7, 2023
Peer-review started: September 7, 2023
First decision: September 20, 2023
Revised: September 29, 2023
Accepted: October 16, 2023
Article in press: October 16, 2023
Published online: November 24, 2023
Processing time: 76 Days and 1 Hours
Core Tip

Core Tip: We aimed to identify the high-risk factors of breast cancer brain metastasis (BCBM) and conducted prognostic analyses. Sixty-eight BCBM patients diagnosed and treated in the Air Force Medical Center in 2000–2022 were enrolled. Patients with human epidermal growth factor receptor 2 overexpressing and triple-negative breast cancer were more prone to BM and had shorter survival time. Late tumor stage and lung metastasis were independent risk factors for BM. The presence or absence of neurological symptoms and bone metastasis, and molecular type were independent prognostic factors for BCBM. Early screening of high-risk patients for BM helps improve survival rate.